Trial Profile
A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2021
Price :
$35
*
At a glance
- Drugs Anti-COVID-19 immunoglobulin-Kamada (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions
- Sponsors Kamada
- 31 Mar 2021 According to a Kamada media release, the effect of the treatment on neutralization activity is being further analyzed.
- 31 Mar 2021 Topline results presented in a Kamada media release.
- 04 Jan 2021 Status changed from active, no longer recruiting to completed.